+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454843
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastroesophageal Reflux Disease Therapeutics Market is projected to reach USD 5.74 Billion in 2026. It is expected to continue growing at a CAGR of 5.36%, reaching USD 7.88 Billion by 2032.

Gastroesophageal reflux disease therapeutics address a chronic, relapsing condition characterized by reflux of gastric contents that causes troublesome heartburn, regurgitation, sleep disruption, reduced quality of life, and complications such as erosive esophagitis, peptic stricture, and Barrett’s esophagus. Clinical guidance from the American College of Gastroenterology supports an empiric proton pump inhibitor trial for typical symptoms without alarm features, while endoscopy and reflux monitoring remain central for complicated, refractory, or diagnostically uncertain cases.

The market is anchored by widely used proton pump inhibitors, H2-receptor antagonists, antacids, alginates, prokinetics in selected settings, and newer potassium-competitive acid blockers. Demand is reinforced by obesity, aging populations, dietary patterns, OTC availability, and growing recognition of non-erosive reflux disease, making GERD therapeutics a high-volume category across prescription and consumer health channels.

Transformative Shifts Reshaping GERD Treatment

The GERD therapeutics landscape is shifting from symptom suppression alone toward precision diagnosis, mucosal healing, durable acid control, and long-term safety management. The 2020 FDA request to remove ranitidine products because of NDMA impurity concerns reshaped H2 blocker use and increased attention to pharmacovigilance, impurity testing, and supply-chain quality.

Innovation is also changing competitive dynamics. Potassium-competitive acid blockers, including vonoprazan, provide rapid and sustained acid suppression and have gained regulatory traction in major markets. At the same time, payers continue to favor low-cost generic PPIs, creating a market where differentiated therapies must prove clinical value in erosive esophagitis healing, symptom relief, adherence, and outcomes in PPI-inadequate responders.

Cumulative Impact of Artificial Intelligence in GERD Therapeutics

Artificial intelligence is beginning to influence GERD therapeutics across discovery, diagnosis, trial design, and real-world evidence. Machine learning can analyze endoscopy images, electronic health records, symptom diaries, pH-impedance datasets, and prescription patterns to identify patients with refractory symptoms, alarm features, adherence gaps, or potential drug-drug interaction risks.

The cumulative impact is operational as much as scientific. AI-enabled pharmacovigilance can detect safety signals earlier, while predictive analytics can support patient segmentation for PPIs, H2 blockers, alginates, PCABs, or procedural referral. For manufacturers and healthcare stakeholders, AI can shorten evidence generation cycles by improving site selection, patient recruitment, real-world outcomes assessment, health economic modeling, and post-launch performance tracking.

Key Regional Insights Across GERD Therapeutics

Asia-Pacific is a high-volume opportunity because of large patient populations, urban dietary changes, growing private healthcare use, and established acid-suppression prescribing, with Japan offering early clinical experience in potassium-competitive acid blockers and several countries expanding access to gastroenterology services. North America remains a premium market driven by high diagnosis rates, OTC and prescription availability, strong gastroenterology networks, FDA approvals, and significant payer scrutiny of differentiated therapies.

Latin America relies heavily on generics and retail pharmacy access, while Brazil and Mexico provide scale through large urban populations, expanding specialty care, and rising use of structured regulatory pathways. Europe combines strong guideline adoption, generic cost containment, and centralized or national health technology assessment, creating a disciplined environment for clinical evidence and reimbursement decisions. The Middle East, especially GCC markets, benefits from healthcare investment, insurance expansion, and high obesity prevalence, whereas Africa remains underdiagnosed, with access tied to affordable generics, diagnostic capacity, trained clinicians, and urban healthcare expansion.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets show uneven but rising demand, shaped by retail pharmacy access, hospital-based specialist care, and expanding middle-class healthcare spending in countries with different reimbursement maturity levels. The GCC is distinguished by high metabolic disease burden, insurance expansion, and investment in tertiary care, supporting demand for both established PPIs and premium therapies where reimbursement and formulary access are available.

The European Union emphasizes regulatory rigor, pharmacovigilance, generics, and health technology assessment, making evidence quality essential for GERD therapeutics. BRICS countries combine large patient pools with strong generic competition, local manufacturing priorities, and growing diagnostic infrastructure. G7 markets lead in clinical research, regulatory oversight, and branded innovation, while NATO should be viewed primarily as a supply-chain resilience and procurement continuity lens rather than a healthcare purchasing bloc, given its diverse national reimbursement systems and separate medicine access policies.

Key Country Insights for Priority GERD Markets

The United States leads commercialization through FDA pathways, OTC-to-prescription channel breadth, broad direct-to-consumer awareness, and rapid uptake of differentiated drugs when outcomes justify coverage. Canada emphasizes evidence-based reimbursement, while Mexico and Brazil are scale markets where COFEPRIS and ANVISA oversight, generic penetration, and private-sector access shape adoption. The United Kingdom, Germany, France, Italy, and Spain are mature European markets where NICE, AMNOG, HAS, and regional procurement frameworks influence pricing, prescribing, and formulary use.

Russia prioritizes domestic supply resilience and continued access to essential generics, while China and India combine large symptomatic populations with strong generic manufacturing, expanding gastroenterology capacity, and increasing use of endoscopy in urban centers. Japan is a benchmark for PCAB adoption, aging-related demand, and structured gastroenterology care. Australia’s TGA and PBS frameworks support evidence-led access, and South Korea’s NHIS environment, advanced endoscopy capacity, and strong hospital networks support structured diagnosis, monitoring, and treatment optimization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence over incremental positioning. Clinical programs should demonstrate healing rates, sustained symptom control, nighttime relief, adherence benefits, safety, and value in patients with inadequate response to standard PPIs. Real-world evidence should be built early to support payer discussions, treatment pathway inclusion, and guideline relevance.

Commercial teams should balance branded innovation with high-volume generic realities, invest in physician and pharmacist education, and segment patients by disease severity, diagnostic confirmation, alarm features, and treatment history. Supply-chain quality, impurity surveillance, responsible OTC communication, and digital adherence tools should be integrated into lifecycle strategy to protect trust, support appropriate use, and expand access.

Research Methodology

This executive summary is grounded in a structured review of clinical guidelines, regulatory communications, peer-reviewed literature, public health datasets, healthcare policy sources, and publicly available therapeutic class information. Core references include guidance from gastroenterology societies, FDA and EMA regulatory information, national reimbursement frameworks, and epidemiology inputs from recognized public health institutions.

Insights were triangulated across therapeutic class dynamics, patient pathways, reimbursement environments, regional healthcare capacity, regulatory trends, and technology adoption signals. The methodology emphasizes verified secondary research, consistency checks across authoritative sources, and market interpretation aligned with clinical practice rather than unsupported forecasting, market sizing, or market share claims.

Conclusion

GERD therapeutics remain a resilient and clinically essential category because reflux symptoms are common, recurrent, and often require long-term management. Generic PPIs continue to anchor treatment volume, but innovation is expanding around PCABs, optimized formulations, digital monitoring, and evidence-based treatment pathways for refractory or complicated disease.

The most successful stakeholders will align clinical differentiation with payer value, regulatory quality, patient adherence, and regional access realities. As AI, real-world evidence, and precision diagnosis mature, GERD therapeutics will move toward more targeted care models that improve symptom control, safety oversight, and resource efficiency.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Pharmacologic Therapies
7.2.1. Proton Pump Inhibitors (PPIs)
7.2.2. H2 Receptor Antagonists
7.2.3. Antacid
7.2.4. Mucosal Coating Agent
7.2.4.1. Sucralfate & Coating Agents
7.2.4.2. Alginates/Raft Formers
7.3. Surgical Interventions
7.4. Device-Based Therapies
8. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.3. Liquid
8.4. Suspension
8.5. Tablet
9. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Injectable
10. Gastroesophageal Reflux Disease Therapeutics Market, by Medicine Type
10.1. Introduction
10.2. Over-The-Counter
10.3. Prescription
11. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Status
11.1. Introduction
11.2. Branded
11.3. Generic
12. Gastroesophageal Reflux Disease Therapeutics Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Gastroesophageal Reflux Disease Therapeutics Market, by End User
14.1. Introduction
14.2. Home Care Settings
14.3. Hospitals
14.4. Specialty Clinics
15. Gastroesophageal Reflux Disease Therapeutics Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Gastroesophageal Reflux Disease Therapeutics Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Gastroesophageal Reflux Disease Therapeutics Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. Japan
17.5. India
17.6. United Kingdom
17.7. France
17.8. Canada
17.9. Australia
17.10. Italy
17.11. South Korea
17.12. Brazil
17.13. Mexico
17.14. Russia
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AstraZeneca plc
19.2. Aurobindo Pharma Limited
19.3. Bayer AG
19.4. Cadila Pharmaceuticals Ltd.
19.5. Camber Pharmaceuticals, Inc.
19.6. Daewoong Pharmaceutical Co., Ltd.
19.7. Dr. Reddy’s Laboratories Limited
19.8. Eisai Co., Ltd.
19.9. Elite Wealth Ltd.
19.10. Haleon plc
19.11. HK inno.N Co., Ltd.
19.12. Ironwood Pharmaceuticals, Inc.
19.13. Johnson & Johnson Services, Inc.
19.14. Lupin Limited
19.15. Onconic Therapeutics Inc.
19.16. Pfizer Inc.
19.17. Phathom Pharmaceuticals, Inc.
19.18. RaQualia Pharma Inc.
19.19. Reckitt Benckiser Group plc
19.20. Sandoz Group AG
19.21. Sanofi S.A.
19.22. Sebela Pharmaceuticals Inc.
19.23. Sun Pharmaceutical Industries Limited
19.24. Takeda Pharmaceutical Company Limited
19.25. Teva Pharmaceutical Industries Ltd.
19.26. The Procter & Gamble Company
19.27. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTACID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTACID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTACID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MILD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MILD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MODERATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SEVERE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 109. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 110. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 111. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 112. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 114. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 115. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 116. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 143. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 144. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 145. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 147. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 148. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 149. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 165. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 166. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 167. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 168. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 170. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 171. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 172. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 177. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 178. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 179. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 180. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 181. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 182. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 183. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 198. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 199. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 200. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 201. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 203. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 204. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 205. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 210. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 211. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 212. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 214. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 216. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 220. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 221. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 222. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 223. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 225. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 226. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 227. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 243. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 244. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 245. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 246. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 248. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 249. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 250. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 254. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 255. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 256. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 257. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 259. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 260. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 261. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 265. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 266. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 267. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 268. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 270. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 271. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 272. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 275. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 277. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 278. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 279. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 280. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 281. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 282. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 283. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 298. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 299. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2017-2032 (USD MILLION)
TABLE 300.

Companies Mentioned

  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Camber Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Eisai Co., Ltd.
  • Elite Wealth Ltd.
  • Haleon plc
  • HK inno.N Co., Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Onconic Therapeutics Inc.
  • Pfizer Inc.
  • Phathom Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Reckitt Benckiser Group plc
  • Sandoz Group AG
  • Sanofi S.A.
  • Sebela Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.88 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report - Product Image

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Report 2026 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Global Clinical Trials Review, 2025 - Product Image

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Global Clinical Trials Review, 2025

  • Clinical Trials
  • 1457 Pages
  • Global
From
Gastroesophageal Reflux Disease (Gerd) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gastroesophageal Reflux Disease (Gerd) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.